A twice-yearly injection that dramatically cuts the risk of acquiring HIV is one of the most significant advances in prevention in a generation. Yet England’s cost watchdog has declined to fund it on the NHS — a decision that captures the growing tension between medical breakthroughs and what health systems can afford.

What lenacapavir is

NICE (the National Institute for Health and Care Excellence) recommended against NHS funding of Gilead’s lenacapavir for pre-exposure prophylaxis (PrEP) — medicine taken by HIV-negative people to keep them from becoming infected — concluding it is “not value for money in this population.” Lenacapavir is a long-acting antiretroviral that interferes with HIV’s protein shell (its capsid), blocking the virus from multiplying. It was approved by the UK’s MHRA in December 2025 and by the U.S. FDA in June 2025, and is given as an injection just twice a year.

Why the dosing schedule is a big deal

Existing PrEP is highly effective but has a real-world weakness: adherence. The long-established options are daily pills (tenofovir-based regimens such as Truvada and Descovy), and a pill only protects you if you actually take it consistently — a challenge for people facing stigma, unstable housing, or simply the burden of a daily reminder of risk. A shot administered twice a year removes the daily-adherence problem almost entirely. In large clinical trials, lenacapavir demonstrated near-complete protection against HIV acquisition, and global health advocates have hailed it as potentially game-changing — the World Health Organization has recommended long-acting lenacapavir as an additional PrEP option.

Why NICE said no

The sticking point is price. NICE explicitly acknowledged that lenacapavir reduces HIV risk more than daily oral PrEP — so the objection is not about whether it works. Instead, the committee pointed to an existing injectable alternative, GSK’s cabotegravir (Apretude, dosed every two months), and cited uncertainties in the clinical evidence and economic modeling — including how closely trial populations reflect UK demographics, and assumptions about patient preferences and quality-of-life measures. Weighing all that against the cost, NICE judged the price too high to represent good value for the NHS.

This is how health-technology assessment works in England: NICE estimates the health gained (often in quality-adjusted life years) and asks whether a drug’s price is justified by that gain relative to alternatives. It is a cost-effectiveness gate, not a judgment on efficacy — but for patients and advocates, the practical result is the same: no NHS access.

The charities’ response — and what’s next

HIV organizations reacted with dismay. Richard Angell of the Terrence Higgins Trust called lenacapavir “the most exciting innovation in HIV prevention for years,” while Daniel Fluskey of the National AIDS Trust called the decision “a real missed opportunity in the fight to end new HIV transmissions.” Their argument: a twice-yearly option could reach exactly the people daily pills fail, accelerating the UK’s goal of ending new HIV cases.

Importantly, the decision may not be final. A second appraisal committee meeting is scheduled for November 3, 2026 — and such meetings are often where confidential price negotiations between the manufacturer and the NHS shift the arithmetic. A lower agreed price could flip a “not cost-effective” verdict into a recommendation. The episode is a reminder that, increasingly, the barrier to a breakthrough reaching patients is less the science than the price tag. This is health-policy news, not medical advice.